Browse Technologies

• 
• 
• 
• 

The Sodium/Iodide symporter (NIS) is a critical protein that facilitates the active transport of iodide into thyroid cells, essential for synthesizing thyroid hormones. Recent advancements in engineering NIS variants aim to selectively transport oxyanions, offering innovative therapeutic strategies for cancer treatment in the thyroid and elsewhere while minimizing side effects.

Vanderbilt researchers have developed a novel approach to enhance recombinant protein production in mammalian cell culture systems by overexpressing specific metabolic proteins in these cells to achieve higher monoclonal antibody titers and increased cell-specific productivity compared to conventional expression systems.

Despite the success of immune checkpoint inhibitors (ICI) like anti-PD-1 in treating other cancers, these therapeutics have not been demonstrated to effectively treat acute myeloid leukemia (AML). Vanderbilt researchers have identified PD-1H as a potential target for treating AML, opening the door for effective therapy using an ICI molecule.

Vanderbilt researchers have developed an injectable drug delivery vehicle using microparticles (MPs) that not only provide sustained cargo delivery over extended time but also play a therapeutic role themselves in reducing inflammation. This drug delivery platform can be used in treating ocular diseases such as glaucoma and traumatic optic neuropathy, as well as other inflammatory diseases throughout the body like peripheral arterial disease and osteoarthritis.